Full Text: 
<1011>
Summary: 
<498>
CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2023-09-26
Cited: 0
Clicked: 1546
Application of interim PET-CT in first-line treatment decision-making for lymphoma
| ||||||||||||||
Abstract: Recent advances in lymphoma treatment have significantly improved the survival of patients; however, the current approaches also have varying side effects. To overcome these, it is critical to implement individualized treatment according to the patient’s condition. Therefore, the early identification of high-risk groups and targeted treatment are important strategies for prolonging the survival time and improving the quality of life of patients. Interim positron emission tomography-computed tomography (PET-CT) has a high prognostic value, which can reflect chemosensitivity and identify patients for whom treatment may fail under this regimen. To date, many prospective clinical studies on interim PET (iPET)-adapted therapy have been conducted. In this review, we focus on the treatment strategies entailed in these studies, as well as the means and timing of iPET assessment, with the aim of exploring the efficacy and existing issues regarding iPET-adapted treatment. It is expected that the improved use of PET-CT examination can facilitate treatment decision-making to identify precise treatment options.
[1]AllenPB, SavasH, EvensAM, et al., 2021. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood, 137(10):1318-1326.
[2]AndréMPE, GirinskyT, FedericoM, et al., 2017. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol, 35(16):1786-1794.
[3]BaillyC, CléryPF, Faivre-ChauvetA, et al., 2017. Immuno-PET for clinical theranostic approaches. Int J Mol Sci, 18(1):57.
[4]BarringtonSF, MeignanM, 2019. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med, 60(8):1096-1102.
[5]BarringtonSF, TrotmanJ, 2021. The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. Lancet Haematol, 8(1):e80-e93.
[6]BehringerK, MuellerH, GoergenH, et al., 2013. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 trials. J Clin Oncol, 31(2):231-239.
[7]BerthonB, MarshallC, EvansM, et al., 2016. ATLAAS: an automatic decision tree-based learning algorithm for advanced image segmentation in positron emission tomography. Phys Med Biol, 61(13):4855-4869.
[8]BolognaS, Vander BorghtT, BriereJ, et al., 2021. Early positron emission tomography response-adapted treatment in localized diffuse large B-cell lymphoma (aaIPI=0): results of the phase 3 LYSA LNH 09-1B trial. Hematol Oncol, 39(S2):31-32.
[9]BorchmannP, HaverkampH, DiehlV, et al., 2011. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol, 29(32):4234-4242.
[10]BorchmannP, GoergenH, KobeC, et al., 2017. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114):2790-2802.
[11]BorchmannP, PlütschowA, KobeC, et al., 2021. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 22(2):223-234.
[12]BoursierC, PerrinM, BordonneM, et al., 2022. Early 18F-FDG PET flare-up phenomenon after CAR T-cell therapy in lymphoma. Clin Nucl Med, 47(2):e152-e153.
[13]CarrasS, DuboisB, SenecalD, et al., 2018. Interim PET response-adapted strategy in untreated advanced stage Hodgkin lymphoma: results of GOELAMS LH 2007 phase 2 multicentric trial. Clin Lymphoma Myeloma Leuk, 18(3):191-198.
[14]CasasnovasRO, YsebaertL, ThieblemontC, et al., 2017. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood, 130(11):1315-1326.
[15]CasasnovasRO, BouabdallahR, BriceP, et al., 2019. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol, 20(2):202-215.
[16]CashenAF, DehdashtiF, LuoJQ, et al., 2011. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med, 52(3):386-392.
[17]ChesonBD, 2018. PET/CT in lymphoma: current overview and future directions. Semin Nucl Med, 48(1):76-81.
[18]CohenD, LuttwakE, Beyar-Katz, O, et al., 2022. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging, 49(3):953-962.
[19]CoiffierB, LepageE, BrièreJ, et al., 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346(4):235-242.
[20]CottereauAS, VersariA, LoftA, et al., 2018. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood, 131(13):1456-1463.
[21]DemeestereI, RacapeJ, DecheneJ, et al., 2021. Gonadal function recovery in patients with advanced Hodgkin lymphoma treated with a PET-adapted regimen: prospective analysis of a randomized phase III trial (AHL2011). J Clin Oncol, 39(29):3251-3260.
[22]DerlinT, Schultze-FloreyC, WernerRA, et al., 2021. 18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Ann Nucl Med, 35(1):132-138.
[23]DührsenU, MüllerS, HertensteinB, et al., 2018. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol, 36(20):2024-2034.
[24]DupuisJ, IttiE, RahmouniA, et al., 2009. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol, 20(3):503-507.
[25]EertinkJJ, BurggraaffCN, HeymansMW, et al., 2021. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv, 5(9):2375-2384.
[26]EngertA, PlütschowA, EichHT, et al., 2010. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med, 363(7):640-652.
[27]FerméC, EghbaliH, MeerwaldtJH, et al., 2007. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med, 357(19):1916-1927.
[28]FerrariC, MaggialettiN, MasiT, et al., 2021. Early evaluation of immunotherapy response in lymphoma patients by 18F-FDG PET/CT: a literature overview. J Pers Med, 11(3):217.
[29]FiadNL, PratesMV, FernandezI, et al., 2022. P1082: safety and efficacy analysis in older patients treated within the GATLA LH-05 protocol: PET-adapted therapy after 3 cycles of ABVD for all stages of Hodgkin lymphoma. HemaSphere, 6:972-973.
[30]FollowsGA, BarringtonSF, BhullerKS, et al., 2022. Guideline for the first-line management of Classical Hodgkin Lymphoma—a British Society for Haematology guideline. Br J Haematol, 197(5):558-572.
[31]FriedbergJW, 2011. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program, 2011(1):498-505.
[32]FuchsM, GoergenH, KobeC, et al., 2019. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol, 37(31):2835-2845.
[33]FuertesS, SetoainX, Lopez-GuillermoA, et al., 2013. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging, 40(4):496-504.
[34]GallaminiA, HutchingsM, RigacciL, et al., 2007. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol, 25(24):3746-3752.
[35]GallaminiA, RossiA, PattiC, et al., 2019. Consolidation radiotherapy could be omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD. Final analysis of the randomized HD0607 trial. Hematol Oncol, 37(S2):147-148.
[36]GallaminiA, RossiA, PattiC, et al., 2020. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL/FIL HD0607 trial. J Clin Oncol, 38(33):3905-3913.
[37]HanHS, EscalónMP, HsiaoB, et al., 2009. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol, 20(2):309-318.
[38]HertzbergM, GandhiMK, TrotmanJ, et al., 2017. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 102(2):356-363.
[39]ImberBS, SadelainM, DeSelmC, et al., 2020. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. Br J Haematol, 190(1):45-51.
[40]JohnsonP, FedericoM, KirkwoodA, et al., 2016. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med, 374(25):2419-2429.
[41]JostingA, WiedenmannS, FranklinJ, et al., 2003. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol, 21(18):3440-3446.
[42]JuweidME, StroobantsS, HoekstraOS, et al., 2007. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol, 25(5):571-578.
[43]KnowlesSM, WuAM, 2012. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol, 30(31):3884-3892.
[44]KreisslS, GoergenH, BuehnenI, et al., 2021. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol, 8(6):e398-e409.
[45]KurtzDM, SchererF, JinMC, et al., 2018. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol, 36(28):2845-2853.
[46]LaCasceAS, DockterT, RuppertAS, et al., 2021. CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL). J Clin Oncol, 39(S15):7507.
[47]LarsonSM, ErdiY, AkhurstT, et al., 1999. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging, 2(3):159-171.
[48]le GouillS, GhesquièresH, ObericL, et al., 2021. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood, 137(17):2307-2320.
[49]LinC, IttiE, HaiounC, et al., 2007. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med, 48(10):1626-1632.
[50]LuminariS, BiasoliI, VersariA, et al., 2014. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol, 25(2):442-447.
[51]MamotC, KlingbielD, Hitz, F, et al., 2015. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol, 33(23):2523-2529.
[52]MatasarMJ, ZelenetzAD, 2008. Overview of lymphoma diagnosis and management. Radiol Clin North Am, 46(2):175-198.
[53]MatasarMJ, FordJS, RiedelER, et al., 2015. Late morbidity and mortality in patients with Hodgkin’s lymphoma treated during adulthood. J Natl Cancer Inst, 107(4):djv018.
[54]Mehta-ShahN, ItoK, BantilanK, et al., 2019. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood Adv, 3(2):187-197.
[55]MoskowitzCH, SchöderH, Teruya-FeldsteinJ, et al., 2010. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol, 28(11):1896-1903.
[56]MounierN, BriceP, BolognaS, et al., 2014. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0‒2) of the LYSA H34 randomized trial. Ann Oncol, 25(8):1622-1628.
[57]PardalE, CoronadoM, MartínA, et al., 2014. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol, 167(3):327-336.
[58]PavlovskyA, FernandezI, KurganskyN, et al., 2019. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. Br J Haematol, 185(5):865-873.
[59]PavlovskyA, FiadNL, PratesMV, et al., 2022. P1081: PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: long term follow up of the GATLA LH-05 trial. HemaSphere, 6:971-972.
[60]PerskyDO, LiHL, StephensDM, et al., 2020. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup National Clinical Trials Network study S1001. J Clin Oncol, 38(26):3003-3011.
[61]PregnoP, ChiappellaA, BellòM, et al., 2012. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood, 119(9):2066-2073.
[62]PressOW, LiHL, SchöderH, et al., 2016. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol, 34(17):2020-2027.
[63]RadfordJ, IllidgeT, CounsellN, et al., 2015. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med, 372(17):1598-1607.
[64]RicardiU, LevisM, EvangelistaA, et al., 2021. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Adv, 5(21):4504-4514.
[65]RigacciL, PucciniB, ZinzaniPL, et al., 2015. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the Fondazione Italiana Linfomi (FIL). Am J Hematol, 90(6):499-503.
[66]SafarV, DupuisJ, IttiE, et al., 2012. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol, 30(2):184-190.
[67]SehnLH, ScottDW, VillaD, et al., 2019. Long-term follow-up of a PET-guided approach to treatment of limited-stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood, 134(S1):401.
[68]ShahNN, NagleSJ, TorigianDA, et al., 2018. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy, 20(12):1415-1418.
[69]ShaikhPM, AliteF, PuglieseN, et al., 2020. Consolidation radiotherapy following positron emission tomography complete response in early-stage Hodgkin lymphoma: a meta-analysis. Leuk Lymphoma, 61(7):1610-1617.
[70]SieniawskiM, ReinekeT, JostingA, et al., 2008. Assessment of male fertility in patients with Hodgkin’s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol, 19(10):1795-1801.
[71]StephensDM, LiHL, SchöderH, et al., 2019. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 134(15):1238-1246.
[72]StewartDA, KloiberR, OwenC, et al., 2014. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. Leuk Lymphoma, 55(9):2064-2070.
[73]StrausDJ, JungSH, PitcherB, et al., 2018. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood, 132(10):1013-1021.
[74]SwinnenLJ, LiHL, QuonA, 2015. Response-adapted therapy for aggressive non-Hodgkin’s lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol, 170(1):56-65.
[75]ToledanoMN, DesbordesP, BanjarA, et al., 2018. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging, 45(5):680-688.
[76]VijenthiraA, ChanK, CheungMC, et al., 2020. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Lancet Haematol, 7(2):e146-e156.
[77]VillaD, SehnLH, Aquino-ParsonsC, et al., 2018. Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. Haematologica, 103(12):e590-e593.
[78]VivianiS, ZinzaniPL, RambaldiA, et al., 2011. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med, 365(3):203-212.
[79]ZanoniL, MattanaF, CalabròD, et al., 2021. Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. Eur J Radiol, 141:109793.
[80]ZasadnyKR, KisonPV, FrancisIR, et al., 1998. FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Positron Imaging, 1(2):123-129.
[81]ZhuCT, ZhaoY, YuF, et al., 2021. Tumor flare reaction in a classic Hodgkin lymphoma patient treated with brentuximab vedotin and tislelizumab: a case report. Front Immunol, 12:756583.
[82]ZinzaniPL, BroccoliA, GioiaDM, et al., 2016. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol, 34(12):1376-1385.
Linlin HUANG, Yi ZHAO, Jingsong HE. Application of interim PET-CT in first-line treatment decision-making for lymphoma[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2200644
@article{title="Application of interim PET-CT in first-line treatment decision-making for lymphoma",
author="Linlin HUANG, Yi ZHAO, Jingsong HE",
journal="Journal of Zhejiang University Science B",
year="in press",
publisher="Zhejiang University Press & Springer",
doi="https://doi.org/10.1631/jzus.B2200644"
}
%0 Journal Article
%T Application of interim PET-CT in first-line treatment decision-making for lymphoma
%A Linlin HUANG
%A Yi ZHAO
%A Jingsong HE
%J Journal of Zhejiang University SCIENCE B
%P 905-921
%@ 1673-1581
%D in press
%I Zhejiang University Press & Springer
doi="https://doi.org/10.1631/jzus.B2200644"
TY - JOUR
T1 - Application of interim PET-CT in first-line treatment decision-making for lymphoma
A1 - Linlin HUANG
A1 - Yi ZHAO
A1 - Jingsong HE
J0 - Journal of Zhejiang University Science B
SP - 905
EP - 921
%@ 1673-1581
Y1 - in press
PB - Zhejiang University Press & Springer
ER -
doi="https://doi.org/10.1631/jzus.B2200644"
Click to get updates and verify authenticity.
Open peer comments: Debate/Discuss/Question/Opinion
<1>